While one NSCLC patient was treated with combined BRAF and MEK inhibition due to the identification of a BRAF V600E mutation, four patients with NSCLC showed an aberration in EGFR (either EGFR Del19 or EGFR L858R) and were treated with osimertinib (Figure 2A and Supplementary Figure S6A). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.